XML 78 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Narrative) (Details)
1 Months Ended 12 Months Ended 36 Months Ended
Nov. 01, 2017
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2018
shares
Oct. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
May 31, 2020
USD ($)
Oct. 01, 2019
USD ($)
Jan. 01, 2019
USD ($)
Sep. 30, 2018
Revenue               $ 3,049,104 $ 5,793,849          
Accumulated deficit   $ (104,597,748)           (104,597,748) (84,580,180)          
Net loss               $ (20,384,716) $ (16,591,293)          
Number of reportable segments | segment               1            
Percentage of non-controlling interest acquired   15.00%           15.00% 15.00%          
Restricted cash from cash flows   $ 9,039,887           $ 9,039,887 $ 22,154,251 $ 9,765,359        
Cash balance insured   250,000           250,000 250,000          
Cash balance uninsured   8,474,836           8,474,836            
Assets transfer from level 1 to level 2   0           0 0          
Assets transfer from level 2 to level 1   0           0 0          
Liabilities transfer from level 1 to level 2   0           0 0          
Liabilities transfer from level 2 to level 1   0           0 0          
Assets transfer in to level 3               0 0          
Assets transfer out of level 3               0 0          
Liabilities transfer in to level 3               0 0          
Liabilities transfer out of level 3               0 0          
Fair value of the contingent consideration               613,290 495,936          
Revenue From Contract With Customer Including Assessed Tax               3,049,104 5,793,849          
Unrecognized tax benefit   0           $ 0 $ 0          
Federal corporate tax rate               21.00%   34.00%        
Right-of-use asset   $ 2,287,500           $ 2,287,500       $ 2,000,000    
ASU 2016-02                            
Right-of-use asset                         $ 520,399  
Lease liabilities                         $ 528,253  
Lab equipment                            
Useful life               P5Y            
Computers                            
Useful life               P3Y            
Furniture and fixtures and leasehold improvements                            
Useful life               P8Y            
Heat I                            
Ownership interest in subsidiary   100.00% 100.00%         100.00% 100.00%          
Pelican Therapeutics, Inc.                            
Ownership interest in subsidiary   85.00% 85.00%         85.00% 85.00%         80.00%
CPRIT                            
Deferred revenue $ 3,400,000 $ 3,400,000           $ 3,400,000            
Grant receivable $ 200,000                          
CPRIT | Minimum                            
Period of maintenance of employment levels 7 years                          
CPRIT | Grant revenue                            
Grant receivable   $ 1,500,000           $ 1,500,000            
Heat I, Inc. and Pelican                            
Shares issued in acquisition | shares     35,000                      
Pelican Therapeutics, Inc.                            
Percentage of voting interests acquired in acquisition   85.00%           85.00% 80.00% 80.00%        
Percentage of non-controlling interest acquired   20.00%           20.00%            
Amount awarded from CPRIT grant           $ 15,200,000 $ 15,200,000       $ 15,200,000      
Contract value               $ 10,300,000            
Pelican Therapeutics, Inc. | Grant revenue                            
Revenue               10,300,000            
Revenue From Contract With Customer Including Assessed Tax               10,300,000            
Grant receivable   $ 1,500,000           $ 1,500,000            
Pelican Therapeutics, Inc. | First tranche | Grant revenue                            
Revenue         $ 1,800,000                  
Revenue From Contract With Customer Including Assessed Tax         $ 1,800,000                  
Pelican Therapeutics, Inc. | Second tranche | Grant revenue                            
Revenue       $ 6,500,000                    
Revenue From Contract With Customer Including Assessed Tax       $ 6,500,000                    
Pelican Therapeutics, Inc. | Third Tranche | Grant revenue                            
Revenue   5,400,000                        
Revenue From Contract With Customer Including Assessed Tax   $ 5,400,000